Publications for Xianzheng Zhou Xianzheng_Zhou@nymc.edu

NYMC School of Medicine
  • Vallera, D. A., Felices, M., McElmurry, R., McCullar, V., Zhou, X., Schmohl, J. U., . . . Miller, J. S. (2016). IL15 Trispecific Killer Engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clinical Cancer Research, 22(14), 3440-3450. doi:10.1158/1078-0432.CCR-15-2710

  • Huang, X., Park, H., Greene, J., Moy, F., Hamby, C. V., Cairo, M. S., . . . Zhou, X. (2015). IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas. PLoS One, 10(7), [Article: e0133152]. doi:10.1371/journal.pone.0133152

  • Park, H., Huang, X., Lu, C., Cairo, M. S., & Zhou, X. (2015). MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteins. The Journal of Biological Chemistry, 290(5), 2831-2841. doi:10.1074/jbc.M114.591420

  • Huang, X., Greene, J., Chu, Y., Hamby, C.Cairo, M. S., . . . Zhou, X. (2014). Chimeric antigen receptor (CAR) T cell immunotherapy for poor risk sarcomas. Biology of Blood and Marrow Transplantation, 20(2 Suppl), S184-S185.

  • Lu, C., Chen, J., Xu, H. G., Zhou, X., He, Q., Li, Y. L., . . . Xu, Z. X. (2014). MIR106B and MIR93 prevent removal of bacteria from epithelial cells by disrupting ATG16L1-mediated autophagy. Gastroenterology, 146(1), 188-199. doi:10.1053/j.gastro.2013.09.006